Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actimag is an oral solution containing magnesium pidolate, a highly bioavailable organic salt of magnesium. It is indicated for the prevention and treatment of magnesium deficiency (hypomagnesemia) in adults and adolescents. Magnesium is an essential mineral that serves as a cofactor for over 300 enzymatic reactions in the body, playing a critical role in energy metabolism, protein synthesis, muscle contraction, and neurochemical transmission. At the cellular level, magnesium acts as a physiological calcium antagonist, modulating voltage-gated calcium channels and blocking N-methyl-D-aspartate (NMDA) glutamate receptors to regulate neuronal excitability. Actimag is developed and marketed by Faes Farma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium pidolate.